New treatment option for older patients with blood cancer
Researchers are a step closer to offering older patients with an aggressive blood cancer, acute myeloid leukaemia (AML), a new less-toxic treatment option.
COVID-19: Find out about our screening clinic - and note our current visitor restrictions
Our Clinical Haematology service is affiliated with the laboratory and clinical research conducted by the Australian Centre for Blood Diseases (ACBD).
ACBD is a leading national and international blood diseases centre with recognised research, treatment, and educational programs for blood diseases. ACBD is affiliated with The Alfred, Monash University, Eastern Health and Southern Health.
Research is divided into two main groups:
For more information about our research groups, teaching and education programs, visit the Australian Centre for Blood Diseases.
Prof Harshal Nandurkar is the Director of Clinical Haematology and head of the Australian Centre for Blood Diseases.
Prof Andrew Spencer is the Head of our Malignant Haematology & Stem Cell Transplantation Service.
As the Director of Research, Stephen Jane is responsible to the Chief Executive for the strategic direction and governance of research at Alfred Health.
Researchers are a step closer to offering older patients with an aggressive blood cancer, acute myeloid leukaemia (AML), a new less-toxic treatment option.
A complex surgery to remove chronic blood clots from arteries in the lungs is giving Australians and New Zealanders a second chance.
The Alfred and Monash University are set to establish Australia’s first dedicated blood cancer research centre, thanks to a $1.2 million grant from the Australian Cancer Research Foundation (ACRF).